CERE 120

N/A

Report date: 2023/10/26 16:56:46

Base Information

Drug NameCERE 120
Drug Alias NameNeurturin gene therapyAAV2-neurturinAAV2-NTNAAV-NRTNAAV-NTN +[6] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2 vector
Mechanisms of ActionNerve tissue proteins modulatorsNeurturin agonists
TargetsNerve tissue proteinsNeurturin
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSangamo Biosciences
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSangamo Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A